This company has been marked as potentially delisted and may not be actively trading. XTL Biopharmaceuticals (XTLB) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsShort InterestTrendsBuy This Stock XTLB vs. MIRA, CVKD, CLSD, XCUR, SNES, GBS, ICU, ENLV, RLYB, and MGRXShould you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include MIRA Pharmaceuticals (MIRA), Cadrenal Therapeutics (CVKD), Clearside Biomedical (CLSD), Exicure (XCUR), Senestech (SNES), GBS (GBS), SeaStar Medical (ICU), Enlivex Therapeutics (ENLV), Rallybio (RLYB), and Mangoceuticals (MGRX). These companies are all part of the "medical" sector. XTL Biopharmaceuticals vs. Its Competitors MIRA Pharmaceuticals Cadrenal Therapeutics Clearside Biomedical Exicure Senestech GBS SeaStar Medical Enlivex Therapeutics Rallybio Mangoceuticals MIRA Pharmaceuticals (NASDAQ:MIRA) and XTL Biopharmaceuticals (NASDAQ:XTLB) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, earnings, risk, valuation, institutional ownership and profitability. Is MIRA or XTLB more profitable? XTL Biopharmaceuticals' return on equity of 0.00% beat MIRA Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets MIRA PharmaceuticalsN/A -406.70% -328.44% XTL Biopharmaceuticals N/A N/A N/A Do analysts recommend MIRA or XTLB? MIRA Pharmaceuticals currently has a consensus price target of $17.00, suggesting a potential upside of 1,072.41%. Given MIRA Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe MIRA Pharmaceuticals is more favorable than XTL Biopharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50XTL Biopharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do institutionals and insiders hold more shares of MIRA or XTLB? 35.2% of MIRA Pharmaceuticals shares are held by institutional investors. Comparatively, 4.4% of XTL Biopharmaceuticals shares are held by institutional investors. 6.7% of MIRA Pharmaceuticals shares are held by insiders. Comparatively, 29.0% of XTL Biopharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, MIRA or XTLB? MIRA Pharmaceuticals has a beta of 1.75, suggesting that its stock price is 75% more volatile than the S&P 500. Comparatively, XTL Biopharmaceuticals has a beta of 1.08, suggesting that its stock price is 8% more volatile than the S&P 500. Which has preferable valuation & earnings, MIRA or XTLB? XTL Biopharmaceuticals has higher revenue and earnings than MIRA Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMIRA PharmaceuticalsN/AN/A-$7.85M-$0.49-2.96XTL Biopharmaceuticals$450K15.93-$1.03MN/AN/A Does the media prefer MIRA or XTLB? In the previous week, MIRA Pharmaceuticals had 3 more articles in the media than XTL Biopharmaceuticals. MarketBeat recorded 4 mentions for MIRA Pharmaceuticals and 1 mentions for XTL Biopharmaceuticals. MIRA Pharmaceuticals' average media sentiment score of 0.74 beat XTL Biopharmaceuticals' score of 0.00 indicating that MIRA Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment MIRA Pharmaceuticals Positive XTL Biopharmaceuticals Neutral SummaryMIRA Pharmaceuticals beats XTL Biopharmaceuticals on 8 of the 13 factors compared between the two stocks. Get XTL Biopharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XTLB vs. The Competition Export to ExcelMetricXTL BiopharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$7.60M$415.98M$5.84B$10.14BDividend YieldN/A2.45%5.68%4.60%P/E RatioN/A7.2175.4125.98Price / Sales15.933.36515.81181.13Price / CashN/A8.4137.5660.44Price / Book1.320.8912.156.29Net Income-$1.03M$10.55M$3.29B$271.07M XTL Biopharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XTLBXTL Biopharmaceuticals0.4819 of 5 stars$1.32+16.4%N/AN/A$7.60M$450K0.00N/AMIRAMIRA Pharmaceuticals2.9957 of 5 stars$1.41+2.2%$17.00+1,105.7%+7.4%$26.89MN/A-2.882News CoverageShort Interest ↓Gap UpCVKDCadrenal Therapeutics3.5181 of 5 stars$13.10-2.0%$32.00+144.3%+28.8%$26.86MN/A-1.484Short Interest ↓CLSDClearside Biomedical2.3574 of 5 stars$0.34+0.8%$4.20+1,140.0%-98.3%$26.59M$1.66M-0.9230Stock SplitGap DownXCURExicure1.3764 of 5 stars$4.15-3.5%N/A+142.5%$26.23M$500K-1.0750Positive NewsGap UpSNESSenestech2.8514 of 5 stars$5.08+1.2%$10.00+96.9%+66.7%$25.10M$1.86M-0.9330Short Interest ↓GBSGBSN/A$1.65+6.1%N/A-10.5%$24.49MN/A-2.947News CoverageICUSeaStar Medical0.3931 of 5 stars$0.88+4.6%N/A-82.2%$24.44M$140K-0.332Short Interest ↓ENLVEnlivex Therapeutics2.5415 of 5 stars$1.03-1.0%$10.00+870.9%-31.8%$24.36MN/A-1.7870News CoverageAnalyst ForecastShort Interest ↑RLYBRallybio3.3849 of 5 stars$0.58-1.9%$5.00+758.1%-46.8%$24.35M$640K-0.6240Positive NewsShort Interest ↓MGRXMangoceuticals0.6916 of 5 stars$2.30-3.0%N/A-96.3%$24.24M$620K-0.603News CoverageShort Interest ↑ Related Companies and Tools Related Companies MIRA Pharmaceuticals Competitors Cadrenal Therapeutics Competitors Clearside Biomedical Competitors Exicure Competitors Senestech Competitors GBS Competitors SeaStar Medical Competitors Enlivex Therapeutics Competitors Rallybio Competitors Mangoceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XTLB) was last updated on 9/14/2025 by MarketBeat.com Staff From Our PartnersStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 Bitcoin miner reveals his trading system (free)There are 18,347 cryptocurrencies in the market right now. 99% of them will fail. And trying to pick winner...Crypto Swap Profits | SponsoredExpert Alert: Massive Bubble Could Crash Your WealthOn July 4th, Trump signed the “One Big Beautiful Bill,” adding $3.4 trillion to the national debt — and pushin...American Alternative | SponsoredThe End of Elon Musk…?While headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts